DAX23.564 +0,5%Est505.739 +0,4%MSCI World4.343 -0,1%Top 10 Crypto9,8000 +0,5%Nas22.374 +1,2%Bitcoin64.742 -0,4%Euro1,1498 ±-0,0%Öl103,4 +2,4%Gold5.022 +0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Commerzbank CBK100 Siemens Energy ENER6Y NVIDIA 918422 BYD A0M4W9 Lufthansa 823212 Deutsche Telekom 555750 Bayer BAY001 DroneShield A2DMAA SAP 716460 Volkswagen (VW) vz. 766403 Deutsche Bank 514000 Allianz 840400 TUI TUAG50 Shell (ex Royal Dutch Shell) A3C99G
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schwächer erwartet -- Asiens Börsen mehrheitlich im Minus
Top News
BNP Paribas-Aktie: Vermögensverwaltung soll Gewinn bis 2030 nahezu verdoppeln BNP Paribas-Aktie: Vermögensverwaltung soll Gewinn bis 2030 nahezu verdoppeln
Volkswagen kehrt Nvidia den Rücken – China-Chips sollen die Zukunft der Autos entscheiden Volkswagen kehrt Nvidia den Rücken – China-Chips sollen die Zukunft der Autos entscheiden
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Jazz Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
157,45 EUR -0,30 EUR -0,19 %
STU
182,05 USD +3,42 USD +1,91 %
BTT
finanzen.net zero
Jazz Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.9,57 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JS1K

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIE00B4Q5ZN47

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJAZZ

Jazz Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireJazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
PR NewswireZiihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
PR NewswireJazz Pharmaceuticals to Participate in Upcoming Investor Events
Wer­bungJazz Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireJazz Pharmaceuticals to Participate in Upcoming Investor Events
PR NewswireJazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 An...
PR NewswireJazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at th...
PR NewswireJazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
PR NewswirePositive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Lo...
PR NewswireJazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
PR NewswireJazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
PR NewswireJazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
PR NewswireJazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
PR NewswireFDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
PR NewswireJazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psy...
PR NewswireModeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
PR NewswireJazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
PR NewswireJazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
PR NewswireJazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
PR NewswireJazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
PR NewswireJazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
PR NewswireJazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
PR NewswireJazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
PR NewswireJazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
PR NewswireJazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
PR NewswireJazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
PR NewswireJazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR NewswireZepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
PR NewswireJazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
PR NewswireJazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell ...
PR NewswireJazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ...
PR NewswireJazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated ...
PR NewswireJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR NewswireJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR NewswireJazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Jazz Pharmaceuticals News

Jazz Pharmaceuticals News: auf dieser Seite finden Sie alle Jazz Pharmaceuticals News und Nachrichten zur Jazz Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Jazz Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Jazz Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.